In a mouse model of WAI in ovarian cancer, we reported that the oral administration (gavage) of a second-generation probiotic L. reuteri (LR) that was engineered to synthesize interleukin-22 (LR-IL-22) is a safe and effective intestinal radioprotector [18,19,20]. Here, IL22 is linked to ovarian carcinoma.